Cipla receives EIR from USFDA for API facility in Bengaluru

23 Sep 2019 Evaluate

Cipla has received the Establishment Inspection Report (EIR), indicating closure of the inspection from United States Food and Drug Administration (USFDA). The agency had conducted inspection at API manufacturing facility in Virgonagar, Bengaluru, from July 15-19, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1510.95 10.85 (0.72%)
02-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1729.35
Dr. Reddys Lab 1255.45
Cipla 1510.95
Zydus Lifesciences 916.50
Lupin 2105.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×